How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
21
WST Quote, Financials, Valuation and Earnings
Last price:
$229.74
Seasonality move
:
5.92%
Day range:
$234.88 - $239.06
52-week range:
$187.43 - $348.90
Dividend yield:
0.35%
P/E ratio:
35.63x
P/S ratio:
5.81x
P/B ratio:
5.67x
Volume:
935.5K
Avg. volume:
861.1K
1-year change:
-31.29%
Market cap:
$17.3B
Revenue:
$2.9B
EPS (TTM):
$6.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$795.7M | $1.83 | 9.22% | 34.18% | $345.71 |
|
BDX
Becton, Dickinson & Co.
|
$5.2B | $2.81 | 4.93% | 211.31% | $206.67 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.57% | 76.14% | $124.41 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.8B | $2.27 | 16.35% | 10.81% | $611.82 |
|
MASI
Masimo Corp.
|
$408M | $1.49 | 7.08% | 565.51% | $183.75 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.72 | 9.18% | 11.75% | $292.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$240.53 | $345.71 | $17.3B | 35.63x | $0.22 | 0.35% | 5.81x |
|
BDX
Becton, Dickinson & Co.
|
$201.92 | $206.67 | $57.6B | 34.64x | $1.05 | 2.07% | 2.66x |
|
BSX
Boston Scientific Corp.
|
$93.79 | $124.41 | $139B | 50.17x | $0.00 | 0% | 7.24x |
|
ISRG
Intuitive Surgical, Inc.
|
$522.04 | $611.82 | $185.1B | 66.24x | $0.00 | 0% | 18.81x |
|
MASI
Masimo Corp.
|
$137.67 | $183.75 | $7.4B | 116.80x | $0.00 | 0% | 4.35x |
|
RMD
ResMed, Inc.
|
$257.72 | $292.67 | $37.6B | 26.38x | $0.60 | 0.88% | 7.21x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
9.03% | 1.594 | 1.61% | 2.02x |
|
BDX
Becton, Dickinson & Co.
|
44.09% | -0.449 | 37.48% | 0.47x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.051 | -- | 3.42x |
|
MASI
Masimo Corp.
|
41.99% | 0.887 | 7.4% | 1.68x |
|
RMD
ResMed, Inc.
|
12.15% | 0.549 | 2.12% | 1.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$293.5M | $173.7M | 15.73% | 17.44% | 21.6% | $133.9M |
|
BDX
Becton, Dickinson & Co.
|
$2.8B | $881M | 3.72% | 6.6% | 14.96% | $1B |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
ISRG
Intuitive Surgical, Inc.
|
$1.9B | $864.3M | 16.57% | 16.59% | 30.16% | $735.6M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
West Pharmaceutical Services, Inc. vs. Competitors
-
Which has Higher Returns WST or BDX?
Becton, Dickinson & Co. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 8.37%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Becton, Dickinson & Co.'s return on equity of 6.6%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B -
What do Analysts Say About WST or BDX?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 43.73%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $206.67 which suggests that it could grow by 2.35%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe West Pharmaceutical Services, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 BDXBecton, Dickinson & Co.3 9 0 -
Is WST or BDX More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.236, suggesting its less volatile than the S&P 500 by 76.383%.
-
Which is a Better Dividend Stock WST or BDX?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.35%. Becton, Dickinson & Co. offers a yield of 2.07% to investors and pays a quarterly dividend of $1.05 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BDX?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 35.63x while Becton, Dickinson & Co.'s PE ratio is 34.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 5.81x versus 2.66x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.5.81x 35.63x $804.3M $140M BDXBecton, Dickinson & Co.2.66x 34.64x $5.9B $493M
-
Which has Higher Returns WST or BSX?
Boston Scientific Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 14.91%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About WST or BSX?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 43.73%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 32.64%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Boston Scientific Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 BSXBoston Scientific Corp.26 1 0 -
Is WST or BSX More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.
-
Which is a Better Dividend Stock WST or BSX?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.35%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BSX?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Boston Scientific Corp.'s net income of $755M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 35.63x while Boston Scientific Corp.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 5.81x versus 7.24x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.5.81x 35.63x $804.3M $140M BSXBoston Scientific Corp.7.24x 50.17x $5.1B $755M
-
Which has Higher Returns WST or ISRG?
Intuitive Surgical, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 27.89%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B ISRGIntuitive Surgical, Inc.66.56% $2.21 $17.9B -
What do Analysts Say About WST or ISRG?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 43.73%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 17.2%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 ISRGIntuitive Surgical, Inc.16 10 1 -
Is WST or ISRG More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.
-
Which is a Better Dividend Stock WST or ISRG?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.35%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or ISRG?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 35.63x while Intuitive Surgical, Inc.'s PE ratio is 66.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 5.81x versus 18.81x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.5.81x 35.63x $804.3M $140M ISRGIntuitive Surgical, Inc.18.81x 66.24x $2.9B $799.5M
-
Which has Higher Returns WST or MASI?
Masimo Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 14.46%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About WST or MASI?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 43.73%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 33.47%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Masimo Corp., analysts believe West Pharmaceutical Services, Inc. is more attractive than Masimo Corp..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 MASIMasimo Corp.4 3 0 -
Is WST or MASI More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.337%.
-
Which is a Better Dividend Stock WST or MASI?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.35%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or MASI?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are larger than Masimo Corp. quarterly revenues of $371.5M. West Pharmaceutical Services, Inc.'s net income of $140M is higher than Masimo Corp.'s net income of $53.7M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 35.63x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 5.81x versus 4.35x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.5.81x 35.63x $804.3M $140M MASIMasimo Corp.4.35x 116.80x $371.5M $53.7M
-
Which has Higher Returns WST or RMD?
ResMed, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 26.1%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About WST or RMD?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 43.73%. On the other hand ResMed, Inc. has an analysts' consensus of $292.67 which suggests that it could grow by 13.56%. Given that West Pharmaceutical Services, Inc. has higher upside potential than ResMed, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 RMDResMed, Inc.8 7 1 -
Is WST or RMD More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.416%.
-
Which is a Better Dividend Stock WST or RMD?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.35%. ResMed, Inc. offers a yield of 0.88% to investors and pays a quarterly dividend of $0.60 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or RMD?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than ResMed, Inc.'s net income of $348.5M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 35.63x while ResMed, Inc.'s PE ratio is 26.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 5.81x versus 7.21x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.5.81x 35.63x $804.3M $140M RMDResMed, Inc.7.21x 26.38x $1.3B $348.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 1.86% over the past day.
Buy
71
CLS alert for Jan 29
Celestica, Inc. [CLS] is down 16.01% over the past day.
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is down 13.53% over the past day.
